Department of Thoracic Oncology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Thoracic Oncology, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.
Clin Lung Cancer. 2021 Jan;22(1):1-5. doi: 10.1016/j.cllc.2020.10.013. Epub 2020 Oct 24.
In cases of non-small-cell lung cancer (NSCLC), molecular-targeted therapy has shown remarkable improvements in the survival and safety compared with conventional chemotherapy. Recently, the tropomyosin receptor kinase (TRK) inhibitors entrectinib and larotrectinib were approved in the United States, Europe, and elsewhere for patients with a neurotrophic tropomyosin-related kinases (NTRK) gene fusion-positive solid tumors, including NSCLC. Furthermore, next-generation TRK inhibitors that are sensitive to certain secondary mutations mediating resistance to entrectinib or larotrectinib are also being tested in ongoing clinical trials. Although the prevalence of NTRK gene fusions among patients with NSCLC is only approximately 1%, the detection of NTRK gene fusions has become more important with the development of such TRK inhibitors. In the present review, we summarize the various diagnostic techniques for NTRK gene fusion and the effects of TRK inhibitors in NTRK fusion-positive NSCLC.
在非小细胞肺癌（NSCLC）中，与传统化疗相比，分子靶向治疗在生存和安全性方面显示出显著改善。最近，原肌球蛋白受体激酶（TRK）抑制剂恩曲替尼和拉罗替尼在美国、欧洲和其他地方获得批准，用于治疗神经生长因子受体激酶（NTRK）基因融合阳性的实体瘤患者，包括 NSCLC。此外，正在进行的临床试验还在测试对恩曲替尼或拉罗替尼耐药的某些继发突变敏感的下一代 TRK 抑制剂。虽然 NSCLC 患者中 NTRK 基因融合的发生率仅约为 1%，但随着此类 TRK 抑制剂的发展，检测 NTRK 基因融合变得更加重要。在本综述中，我们总结了 NTRK 基因融合的各种诊断技术以及 TRK 抑制剂在 NTRK 融合阳性 NSCLC 中的作用。
